Literature DB >> 23580134

Adapted ECMO criteria for newborns with persistent pulmonary hypertension after inhaled nitric oxide and/or high-frequency oscillatory ventilation.

Saskia van Berkel1, Mathijs Binkhorst, Arno F J van Heijst, Marc H W A Wijnen, Kian D Liem.   

Abstract

PURPOSE: Early prediction of extracorporeal membrane oxygenation (ECMO) requirement in term newborns with persistent pulmonary hypertension (PPHN), partially responding to inhaled nitric oxide (iNO) and/or high-frequency oscillatory ventilation (HFOV), based on oxygenation parameters.
METHODS: This was a retrospective cohort study in 53 partial responders from among 133 term newborns with PPHN born between 2002 and 2007. Alveolar-to-arterial oxygen gradient (AaDO₂) values were determined in these 53 partial responders during the initial 72 h of iNO and/or HFOV treatment and compared between newborns who ultimately did (n = 11) and did not (n = 42) need ECMO.
RESULTS: Over 72 h, partial responders not requiring ECMO showed a more profound AaDO₂ decrease than those who needed ECMO (median decline 242.5 mmHg, IQR 144 to 353 mmHg, vs. 35 mmHg, IQR -15 to 123 mmHg; p = 0.0007). A decline of <123 mmHg over 72 h predicted the need for ECMO (sensitivity 82 %, specificity 79 %). At 72 h, AaDO₂ was significantly lower in partial responders without the need for ECMO than in those who did need ECMO (median 369 mmHg, IQR 258 to 478 mmHg, vs. 570 mmHg IQR 455 to 590 mmHg; p = 0.0008). An AaDO₂ >561 mmHg at 72 h predicted the need for ECMO (sensitivity 64 %, specificity 95 %, positive predictive value 78 %).
CONCLUSIONS: In term newborns with PPHN partially responding to iNO and/or HFOV, oxygenation-based prediction of the need for ECMO appears to be possible after 72 h. ECMO centers are encouraged to develop their own prediction model in order to prevent both lung damage and unnecessary ECMO runs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23580134     DOI: 10.1007/s00134-013-2907-y

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  25 in total

1.  Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn.

Authors:  H Christou; L J Van Marter; D L Wessel; E N Allred; J W Kane; J E Thompson; A R Stark; S Kourembanas
Journal:  Crit Care Med       Date:  2000-11       Impact factor: 7.598

2.  Diagnosis-related criteria in the consideration of extracorporeal membrane oxygenation in neonates previously treated with high-frequency jet ventilation.

Authors:  S Baumgart; R B Hirschl; S Z Butler; C E Coburn; A R Spitzer
Journal:  Pediatrics       Date:  1992-03       Impact factor: 7.124

3.  Inhaled nitric oxide in hypoxaemic newborns who are candidates for extracorporeal life support.

Authors:  P Biban; D Trevisanuto; A Pettenazzo; P Ferrarese; E Baraldi; F Zacchello
Journal:  Eur Respir J       Date:  1998-02       Impact factor: 16.671

4.  Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure.

Authors: 
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

5.  Criteria for extracorporeal membrane oxygenation in a population of infants with persistent pulmonary hypertension of the newborn.

Authors:  R Beck; K D Anderson; G D Pearson; J Cronin; M K Miller; B L Short
Journal:  J Pediatr Surg       Date:  1986-04       Impact factor: 2.545

6.  Four patterns of response to inhaled nitric oxide for persistent pulmonary hypertension of the newborn.

Authors:  A P Goldman; R C Tasker; S G Haworth; P E Sigston; D J Macrae
Journal:  Pediatrics       Date:  1996-10       Impact factor: 7.124

7.  Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group.

Authors:  R H Clark; T J Kueser; M W Walker; W M Southgate; J L Huckaby; J A Perez; B J Roy; M Keszler; J P Kinsella
Journal:  N Engl J Med       Date:  2000-02-17       Impact factor: 91.245

8.  Predictability model of the need for extracorporeal membrane oxygenation in neonates with meconium aspiration syndrome treated with inhaled nitric oxide.

Authors:  Philippe Friedlich; Shahab Noori; James Stein; Cathy Shin; Cartland Burns; Rangansamy Ramanathan; Istvan Seri
Journal:  J Pediatr Surg       Date:  2005-07       Impact factor: 2.545

Review 9.  Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn.

Authors:  G Ganesh Konduri; U Olivia Kim
Journal:  Pediatr Clin North Am       Date:  2009-06       Impact factor: 3.278

10.  The VICI-trial: high frequency oscillation versus conventional mechanical ventilation in newborns with congenital diaphragmatic hernia: an international multicentre randomized controlled trial.

Authors:  Lieke van den Hout; Dick Tibboel; Sanne Vijfhuize; Harma te Beest; Wim Hop; Irwin Reiss
Journal:  BMC Pediatr       Date:  2011-11-02       Impact factor: 2.125

View more
  3 in total

Review 1.  Inhaled pulmonary vasodilators: a narrative review.

Authors:  Kai Liu; Huan Wang; Shen-Ji Yu; Guo-Wei Tu; Zhe Luo
Journal:  Ann Transl Med       Date:  2021-04

2.  Therapeutic effects and outcomes of rescue high-frequency oscillatory ventilation for premature infants with severe refractory respiratory failure.

Authors:  Jen-Fu Hsu; Mei-Chin Yang; Shih-Ming Chu; Lan-Yan Yang; Ming-Chou Chiang; Mei-Yin Lai; Hsuan-Rong Huang; Yu-Bin Pan; Ren-Huei Fu; Ming-Horng Tsai
Journal:  Sci Rep       Date:  2021-04-19       Impact factor: 4.379

3.  Year in review in Intensive Care Medicine 2013: III. Sepsis, infections, respiratory diseases, pediatrics.

Authors:  Jean-Francois Timsit; Giuseppe Citerio; Jan Bakker; Matteo Bassetti; Dominique Benoit; Maurizio Cecconi; J Randall Curtis; Glenn Hernandez; Margaret Herridge; Samir Jaber; Michael Joannidis; Laurent Papazian; Mark Peters; Pierre Singer; Martin Smith; Marcio Soares; Antoni Torres; Antoine Vieillard-Baron; Elie Azoulay
Journal:  Intensive Care Med       Date:  2014-02-12       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.